In 1994, pharmaceutical giant Johnson & Johnson released Risperdal,
an antipsychotic drug that, over the next few years, would yield hundreds
of millions of dollars for the company. It has since been determined,
however, that much of those profits were due to illegal, "off-label"
promotions by Johnson & Johnson and the resulting lawsuits from Risperdal's
harmful effects continue to crop up, even today in 2015. Huffington Post
Highline has now launched a new, in-depth series,
"America's Most Admired Lawbreaker," chronicling the Risperdal scandal, Johnson & Johnson's business-as-usual
breaking of regulations, and the effect that big pharma continues to have
on economies—and patients—around the world.
The Risperdal Story
By the late 1980s, Haldol, Johnson & Johnson's popular antipsychotic
drug had come "off-patent" and effective, generic knock-offs
began flooding the market. In response, the company developed Risperdal,
an antipsychotic drug that was not only meant to replace Haldol, but expand
its application into prominent mental disorder treatments, such as for
depression and anxiety.
From the beginning, Johnson & Johnson sparred with the FDA over their
plan to market Risperdal on two key points. One was that Johnson &
Johnson wanted to claim that Risperdal was more effective than Haldol.
Due to lacking clinical data to support that claim, the FDA prohibited
it. Secondly, Johnson & Johnson wanted to market the drug for use
in children and the elderly. Again, the FDA prohibited that course of
action, due to insufficient data that supported safe usage in both of
those patient types.
Issues with Johnson & Johnson's compliance with the FDA's ruling
is best exemplified in the case of Austin Pledger, an Alabama boy (now
21) who was prescribed Risperdal to treat his autism. Because of the drug,
Pledger developed breasts and an investigation into Johnson & Johnson's
internal documents revealed that the company not only knew of possible
hormonal effects of the drug, but continued to promote it to pediatricians anyway.
Johnson & Johnson vehemently asserted that they never consciously violated
"vague" government laws that prohibit the promotion of drugs
to certain populations. A jury awarded the Pledger family $2.5 million
and Johnson & Johnson has since settled thousands of other cases involving
Risperdal. Even as more lawsuits loom, however, the company is gearing
up to launch a whole new line of pharmaceuticals.
Big Pharma & Breaking the Law
Perhaps most troubling about "America's Most Admired Lawbreaker"
is its implications about the future of "big pharma" companies
like Johnson & Johnson. The company and its competitors now have the
eyes of Wall Street upon them and make more far more money than other
perceived "boom" industries (such as Silicon Valley). Bringing
legal action against the highest decision-makers at these companies is
nearly impossible and bolstering profits by illegally marketing drugs
may be built into the very framework of how the industry produces revenue.
Even more concerning, the companies are so lucrative that they can easily
absorb any legal penalties, even ones as big as the Pledger ruling.
“Oh, they’ve [the companies] already reserved for that stuff,”
one stock analyst told the Huffington Post writer. "It’s their
cost of doing business... It’s just not a big deal."
Have you or a loved one been harmed by a drug? If so,
Christian & Davis LLC is ready to hear from you. Our dedicated team of Greenville personal injury
attorneys have nearly a century of collective legal experience and have
recovered millions of dollars for our clients in need. We are not afraid
to advocate for our clients and take those responsible for their pain
and suffering to task in the courtroom.
Explore your legal options with us today.
Call our team at 864.408.8890 now.